Acute Gout Flare Market to Experience Robust Growth by 2034 - DelveInsight Analysis | Highlighting Key Players Like Dyve Biosciences, Olatec Therapeutics, NOVARTIS PHARMS

Acute gout flare emerging therapies, such as IDYV700, OLT1177 (Dapansutrile), , XRx-026 and others, are expected to boost the Acute Gout Flare Market in the upcoming years.

DelveInsight has launched a new report on "Acute Gout Flare - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the acute gout flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Acute Gout Flare Market Report:

In June 2024, the FDA approved the supplemental New Drug Application (sNDA) for the commercial manufacturing of GLOPERBA, the first and only liquid oral version of colchicine. Gloperba is indicated for the prophylaxis of painful gout flares in adults and offers a precision dosing option, particularly beneficial for patients with chronic kidney disease .​
A novel investigational combination medicine for chronic refractory gout (CRG). The FDA granted Fast Track designation in March 2024, and a rolling Biologics License Application (BLA) has been submitted.​Based on the analysis, the yearly incidence of gout in the UK is 2.68 cases per 1,000 individuals.
Our analysis shows that in the United States, interest in gout has increased due to its rising incidence, now affecting over 8 million Americans.
Men are more likely to develop gout compared to women, due to higher uric acid levels. In Western nations, the condition affects approximately 3-6% of men and 1-2% of women. In certain countries, the prevalence can rise to as high as 10%.
Key acute gout flare companies, such as Dyve Biosciences, XORTX Therapeutics, Shanton Pharma, InventisBio, Olatec Therapeutics, Novartis Pharmaceuticals, and others, are evaluating new drugs to improve the acute gout flare treatment landscape.
Promising acute gout flare pipeline therapies in various stages of development include IDYV700, XRx-026, OLT1177, ILARIS, and others.
Key benefits of the Acute Gout Flare market report:
acute gout flare market report covers a descriptive overview and comprehensive insight of the acute gout flare Epidemiology and acute gout flare market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The acute gout flare market report provides insights into the current and emerging therapies.
The acute gout flare market report provides a global historical and forecasted market covering drug outreach in 7MM.
The acute gout flare market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the acute gout flare market.

Got queries? Click here to know more about the acute gout flare market landscape https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Gout Flare Overview

Gout is a type of inflammatory arthritis caused by the buildup of monosodium urate (MSU) crystals within the joints, typically following a condition known as hyperuricemia. The disease develops through four distinct stages: asymptomatic hyperuricemia, acute gout attacks, intercritical periods (between flares), and, if not properly managed, chronic tophaceous gout. With timely diagnosis and appropriate treatment, gout can be effectively controlled.

Gout attacks can significantly impact a patient's well-being, leading to intense joint pain, inflammation, limited mobility, and a lower quality of life. Epidemiological research indicates that gout has become increasingly common, now affecting over 3% of the adult population in the United States.

Several risk factors contribute to the development of gout, including genetics, age, sex, and dietary habits. These factors can lead to elevated levels of uric acid in the blood, defined as 6.8 mg/dL (or 405 μmol/L) or higher. Hyperuricemia is the leading risk factor for gout. The condition is more frequently observed in men than women and is more common in individuals over 60 years old. Genetic predisposition also plays a significant role in the disease's progression. Diets high in red meat, seafood, sugary beverages, fructose, and alcohol can further increase the likelihood of developing hyperuricemia and, subsequently, gout.

Acute Gout Flare Market Outlook

Treatment for acute gout attacks typically begins with first-line options such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), COX-2 inhibitors, corticosteroids, colchicine, or localized steroid injections. The primary goal of acute treatment is to relieve pain quickly and ensure a complete and rapid resolution of symptoms. However, acute flares often recur, with progressively shorter symptom-free intervals, potentially leading to chronic gout. Chronic cases are characterized by persistent joint inflammation (synovitis), bone erosion, cartilage damage, and the development of tophi.

For patients who experience frequent flares and cannot tolerate NSAIDs, colchicine, or corticosteroids (oral or injectable), the European League Against Rheumatism (EULAR) recommends IL-1 inhibitors. Canakinumab, a long-acting monoclonal antibody targeting IL-1 beta, has been approved by the European Medicines Agency following two randomized controlled trials comparing it to intramuscular triamcinolone acetonide. Additionally, anakinra, an IL-1 receptor antagonist, is used off-label in similar cases. Urate-lowering therapies (ULTs) are also prescribed to maintain healthy serum uric acid levels.

With ongoing research and development surrounding various IL-1 blockers, the treatment landscape for acute gout flares is expected to undergo major changes. These therapies have demonstrated established safety and tolerability profiles, contributing to optimism in the field.

Explore how the acute gout flare market is rising in the upcoming years @ https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Acute Gout Flare Therapies and Key Companies
OLT1177 (Dapansutrile): Olatec Therapeutics
DYV700: Dyve Biosciences
XRx-026: XORTX Therapeutics

To know more about the therapies that are driving the acute gout flare treatment market, visit: https://www.delveinsight.com/sample-request/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Scope of the Acute Gout Flare Market Report

Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Acute Gout Flare Companies:Dyve Biosciences, XORTX Therapeutics, Shanton Pharma, InventisBio, Olatec Therapeutics, Novartis Pharmaceuticals and others
Key Acute Gout Flare Therapies: IDYV700, OLT1177 (Dapansutrile), XRx-026, and others
Acute Gout Flare Therapeutic Assessment: Acute gout flare current marketed and Acute Gout Flare emerging therapies
Acute Gout Flare Market Dynamics: Acute gout flare market drivers and acute gout flare market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Acute Gout Flare Unmet Needs, KOL's views, Analyst's views, Acute Gout Flare Market Access and Reimbursement

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Acute Gout Flare Patient Share (%) Overview at a Glance
5. Acute Gout Flare Market Overview at a Glance
6. Acute Gout Flare Disease Background and Overview
7. Acute Gout Flare Epidemiology and Patient Population
8. Country-Specific Patient Population of Acute Gout Flare
9. Acute Gout Flare Current Treatment and Medical Practices
10. Unmet Needs
11. Acute Gout Flare Emerging Therapies
12. Acute Gout Flare Market Outlook
13. Country-Wise Acute Gout Flare Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Acute Gout Flare Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Acute Gout Flare Market Outlook 2034 @ https://www.delveinsight.com/report-store/acute-gout-flare-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Acute Gout Flare Pipeline Insights, DelveInsight

"Acute Gout Flare Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the acute gout flare market. A detailed picture of the acute gout flare pipeline landscape is provided, including a disease overview and treatment guidelines for acute gout flare. .

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.